Duloxetine Capsules Recalled for N-Nitroso Impurity Exceeding FDA Limits
Breckenridge Pharmaceutical is recalling 11,125 bottles of Duloxetine 20mg capsules nationwide due to N-nitroso-duloxetine impurity above FDA-recommended limits. The impurity was detected during quality control testing.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II drug recall with a detected high-risk pharmaceutical impurity (N-nitroso-duloxetine) above recommended limits, but with no reported illnesses or injuries. Score follows the rubric criterion for risk-of-harm products where injury has not yet been reported.
Plain-English summary
Breckenridge Pharmaceutical, Inc. is recalling Duloxetine delayed-release capsules, 20 mg (NDC 51991-746-05), due to the presence of N-nitroso-duloxetine impurity above FDA-recommended interim limits. This impurity was detected as part of a current Good Manufacturing Practice (cGMP) deviation.
The recall encompasses approximately 11,125 bottles with lot number 240098C and an expiration date of January 2027. The affected capsules were manufactured by Towa Pharmaceutical Europe, S.L. in Martorelles, Barcelona, Spain, and distributed nationwide by Breckenridge Pharmaceutical in Berkeley Heights, New Jersey.
Consumers with this specific lot should contact their pharmacy or healthcare provider for guidance regarding this recall.
The recalled product
- Product
- DULOXETINE (DULOXETINE HYDROCHLORIDE)
- Brand
- DULOXETINE
- Manufacturer
- Breckenridge Pharmaceutical, Inc.
- Category
- Drug
- Hazard
- Affected units
- 11,125
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot#: 240098C
- Expiration: 01/2027.
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 3 recalled by Breckenridge Pharmaceutical, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 3 products in this recall →Related recalls
Same brand · DULOXETINE
- HighDuloxetine 30mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
- HighDuloxetine 60mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
- HighEnovachem duloxetine capsules exceed the nitrosamine acceptable intake limit
FDA (Drugs) · 2026-06-10
- ModerateDuloxetine Delayed-Release Capsules Recalled for Impurity Above Limit
FDA (Drugs) · 2026-05-13
- ModerateDuloxetine Delayed-Release Capsules Recalled for Impurity Above FDA Limit
FDA (Drugs) · 2026-05-13
Same manufacturer · Breckenridge Pharmaceutical, Inc.
See all →- ModerateDuloxetine delayed-release capsules recalled for N-nitroso impurity contamination
FDA (Drugs) · 2026-05-13
- HighDuloxetine delayed-release capsules recalled over a nitrosamine impurity above FDA limits
FDA (Drugs) · 2025-12-10
- HighIntelliVue MX550 patient monitors recalled over an alarm activation issue
FDA (Drugs) · 2025-12-10
- HighDuloxetine capsules recalled over nitrosamine impurity above the safety assessment limit
FDA (Drugs) · 2025-11-05
- HighDuloxetine delayed-release capsules recalled over N-nitroso-duloxetine above interim limit
FDA (Drugs) · 2025-09-17
Same hazard · n nitroso impurity
See all →- HighCinacalcet Tablets Recalled for N-Nitroso Impurity Exceeding Limits
FDA (Drugs) · 2026-07-08
- SevereCinacalcet Tablets Recalled for cGMP Deviations
FDA (Drugs) · 2026-07-08
- ModerateFurosemide tablets recalled for presence of N-nitroso impurity
FDA (Drugs) · 2026-04-29
- SevereFluoxetine Tablets 20 mg Recalled for N-Nitroso Impurity
FDA (Drugs) · 2025-06-11
- SevereCarvedilol Tablets Recalled Due to N-Nitroso Impurity
FDA (Drugs) · 2025-06-04